Navigation Links
Cytokinetics Reports Additional Clinical Trials Data for Ispinesib

liver, lung and lymph node metastases. The duration of response, independently reviewed, ranged from 7.1 weeks to 30.0 weeks. The median time to progression in the treated population was 5.9 weeks. The adverse events were manageable, predictable and consistent with those seen in the Phase I trials of ispinesib. The most common grade 3/4 adverse events observed were neutropenia, febrile neutropenia and neutropenic sepsis.

In addition, GSK has sponsored three dose-escalating Phase Ib clinical trials. Each of these clinical trials was designed to evaluate the safety, tolerability and pharmacokinetics of ispinesib in combination with a leading anti-cancer therapeutic, one in combination with carboplatin, the second in combination with capecitabine, and the third in combination with docetaxel. The clinical trial evaluating ispinesib in combination with capecitabine is closed to enrollment. Final data from this trial are expected in 2007.

Under a November 2006 amendment to its collaboration and license agreement with GSK, Cytokinetics has assumed responsibility for the costs and activities associated with the continued development of the KSP inhibitors, ispinesib and SB-743921, subject to GSK s option to resume responsibility for some or all development and commercialization activities associated with each of these novel drug candidates. Cytokinetics plans to conduct, at its expense, a focused development program for ispinesib in breast cancer specifically designed to supplement the broad series of Phase I and Phase II clinical trials sponsored by GSK that have demonstrated clinical activity in the treatment of patients with metastatic breast cancer and that have shown an acceptable tolerability profile for ispinesib in combination with standard chemotherapeutics.

The NCI has sponsored six additional Phase II clinical trials, evaluating the potential efficacy of ispinesib in an array of different tumor types. Enrollment has been closed for
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Cytokinetics Announces Non-clinical Data to be Presented at the 2007 AACR Annual Meeting
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
(Date:7/31/2014)... 31, 2014 Marken announced today the expansion ... meet the clinical trial logistics growth in Central and ... facility will continue to serve as a regional center ... from the region, and will provide additional storage capacity. ... combine its office and warehouse into a single facility, ...
(Date:7/30/2014)... July 30, 2014  There is still time ... success. The 10th Annual Institute for Supply Management ... Excellence in Supply Management is open for submissions.  ... understanding and importance of supply management by recognizing ... best supply management practices.  Entries are due August ...
(Date:7/30/2014)... 2014 In conjunction with DURECT Corporation,s (Nasdaq: ... press release, you are invited to listen to the ... internet on Thursday, August 7, 2014 at 4:30 pm ... live audio webcast of the presentation will be available ... clicking "Investor Relations."  If you are unable to participate ...
Breaking Medicine Technology:Marken Expands Miami Regional Logistics Center 2Institute for Supply Management, Michigan State University to recognize companies with excellent supply management practices 2DURECT Corporation Invites You to Join its Second Quarter 2014 Earnings Conference Call 2
... May 4, 2012 Medical device and medical ... their products meet quality standards and regulations at ... and product development to manufacturing and post-marketing activity. ... an increasingly competitive marketplace, medical device organizations are ...
... PARSIPPANY, N.J., May 4, 2012  Watson Pharmaceuticals, Inc. (NYSE: ... DeFrancesco has been promoted to the position of Vice ... Ms. DeFrancesco reports to Charles Mayr, Chief Communications Officer ... Watson on June 1, 2012. In this ...
Cached Medicine Technology:Staffing and Performance Benchmarks for Quality Function Highlight New Medical Device Study 2Watson Names Lisa DeFrancesco Vice President, Global Investor Relations 2
(Date:7/31/2014)... Beverly Hills, CA (PRWEB) July 31, 2014 ... president George W. Bush recently underwent partial knee replacement surgery ... right knee less than two months earlier. The story also ... between the procedures and hopes to be back on the ... replacement surgery highlights the benefits of partial knee replacement. ...
(Date:7/31/2014)... 31, 2014 ProtonPACS, a division of ... the National Rural Health Association (NRHA), company officials announced ... understanding the needs of rural health providers nationwide. , ... Health Association,” said Dr. Mark Awh, President of Radsource. ... of ProtonPACS, we are also looking forward to learning ...
(Date:7/31/2014)... 2014) While it is known that members of the ... a new study finds that female enlistees and female ... civilian counterparts. This study was published today in ... on behalf of the Inter-University Seminar on Armed Forces ... Tedrow studied surveys of nearly 9,000 men and women ...
(Date:7/31/2014)... Staying happy in a relationship and loving for years ... get sucked into the logistical ruts they know as their ... kids. , That’s why Couples in Trouble Relationship Expert, ... to Reignite the Spark in Your Marriage TODAY” Guide as ... much better path to happiness, and a far less costly ...
(Date:7/31/2014)... 2014 According to new research ... Mycoprotein), by Type (Tofu, Tofu-Based Product, Tempeh, TVP, ... Global Trends & Forecasts to 2019", defines and ... analysis and forecasting of the market value of ... report also identifies the driving and restraining factors ...
Breaking Medicine News(10 mins):Health News:George W. Bush’s Surgery Highlights the Benefits of Partial Knee Replacement 2Health News:ProtonPACS Announces Pipeline Partnership with the National Rural Health Association. 2Health News:Women in military less likely to drink than civilian women 2Health News:Couples in Trouble Relationship Expert, Dr. Jackie Black, Offers a Gift Guide to Reignite the Spark So Lovers Can Kiss-And-Make-Up 2Health News:Couples in Trouble Relationship Expert, Dr. Jackie Black, Offers a Gift Guide to Reignite the Spark So Lovers Can Kiss-And-Make-Up 3Health News:Meat Substitutes Market Worth $4,622.4 Million by 2019 - New Report by MarketsandMarkets 2Health News:Meat Substitutes Market Worth $4,622.4 Million by 2019 - New Report by MarketsandMarkets 3
... RESULTS, EUR,000,000 2008 ... 92.5 99.3 EBITDA* ... 14.0% 16.1% Current operating income* ... (2.8) (2.7) Net income ...
... central nervous system , , WEDNESDAY, July 30 (HealthDay News) ... depression, at least in mice. , According to the ... Istvan Mody, both of the David Geffen School of ... of a particular class of proteins called GABA receptors ...
... Data from 260 hospitals across the United States has ... to more accurately determine the severity of heart failure in ... mortality and more quickly identifying triage methods and treatment decisions. ... the Journal of the American College of Cardiology . ...
... for Universal, Health Coverage Proposal but Obstacles Remain, According ... ... 30 ,HealthLeaders-InterStudy, a leading provider of managed care market,intelligence, reports ... windfall for the state of New Mexico has resulted in ...
... recently,submitted its bid to the U.S. Department of ... third generation TRICARE South Region contract. If,awarded the ... active,duty, retired and participating reserve and National Guard ... on April 1, 2010., "It is TriServ,s ...
... Sunrise Senior Living,Inc. (NYSE: SRZ ) today ... and webcast to discuss the Company,s 2007 financial ... data.,The call will now be held on Friday, ... will issue its 2007 financial results and second-quarter ...
Cached Medicine News:Health News:PCAS : Half Result 2008 2Health News:Possible Cause of Postpartum Depression Pinpointed 2Health News:Possible Cause of Postpartum Depression Pinpointed 3Health News:New method assesses risks for heart failure patients 2Health News:Gov. Richardson's Healthcare Reform Agenda Gains New Life 2Health News:Sunrise Updates Date and Time of Conference Call to Discuss 2007 Financial Results and Second-Quarter 2008 Preliminary Selected Financial and Operating Data 2
Solid 14 mm blades. Dull finish....
Angled for temporal approach. Open 14 mm rounded blades for patient comfort. Dull finish....
Open 14 mm blades of heavy 1 mm wire. Dull finish. Most popular size or model....
Open wire style blades allow complete manipulation of the phaco tip inside the eye. Lid control is excellent, exposure is maximized, and the likelihood of positive pressure is reduced....
Medicine Products: